Padsevonil
Padsevonil ( , , ; developmental code name UCB-0942) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of epilepsy.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Padsevonil ( , , ; developmental code name UCB-0942) is a synaptic vesicle glycoprotein 2A (SV2A) ligand which is under development for the treatment of epilepsy. It is much more potent than earlier SV2A ligands like levetiracetam and brivaracetam. However, in contrast to its predecessors, padsevonil's chemical structure has been modified such that it is no longer a racetam.
In addition, padsevonil also interacts with synaptic vesicle glycoprotein 2B (SV2B) and 2C (SV2C). The drug is being developed by UCB. As of November 2023, it is in phase 2 clinical trials.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1328693359 under CC BY-SA 4.0; modifications have been made.